S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Arrowhead Pharmaceuticals, Inc. to Post FY2026 Earnings of $10.85 Per Share, Jefferies Financial Group Forecasts (NASDAQ:ARWR)

Last updated on Thursday, November 25, 2021 | 2021 MarketBeat

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Stock analysts at Jefferies Financial Group issued their FY2026 EPS estimates for Arrowhead Pharmaceuticals in a report released on Tuesday, November 23rd. Jefferies Financial Group analyst M. Raycroft anticipates that the biotechnology company will earn $10.85 per share for the year. Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Monday, November 22nd. The biotechnology company reported ($0.61) earnings per share for the quarter, missing the Zacks' consensus estimate of $0.04 by ($0.65). Arrowhead Pharmaceuticals had a negative return on equity of 28.00% and a negative net margin of 116.97%. During the same quarter in the previous year, the business earned ($0.48) earnings per share.

A number of other brokerages have also commented on ARWR. TheStreet raised shares of Arrowhead Pharmaceuticals from a "d+" rating to a "c-" rating in a research report on Thursday, November 4th. HC Wainwright raised their target price on shares of Arrowhead Pharmaceuticals from $95.00 to $100.00 and gave the stock a "buy" rating in a research report on Tuesday, August 10th. SVB Leerink raised their target price on shares of Arrowhead Pharmaceuticals from $44.00 to $45.00 and gave the stock a "market perform" rating in a research report on Tuesday. Finally, Chardan Capital cut their price objective on shares of Arrowhead Pharmaceuticals from $97.00 to $94.00 and set a "buy" rating on the stock in a report on Friday, August 6th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $89.89.

Shares of NASDAQ:ARWR opened at $74.04 on Thursday. The firm has a market cap of $7.72 billion, a PE ratio of -60.20 and a beta of 1.14. The firm's 50 day simple moving average is $67.29 and its 200-day simple moving average is $69.47. Arrowhead Pharmaceuticals has a one year low of $56.05 and a one year high of $93.66.

In other news, Director Adeoye Y. Olukotun sold 5,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Monday, September 13th. The shares were sold at an average price of $63.76, for a total transaction of $318,800.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Christopher Richard Anzalone sold 50,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Friday, October 22nd. The stock was sold at an average price of $65.63, for a total transaction of $3,281,500.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 89,500 shares of company stock valued at $5,945,295. 3.50% of the stock is owned by insiders.

Several institutional investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC increased its holdings in Arrowhead Pharmaceuticals by 619.7% in the first quarter. Cubist Systematic Strategies LLC now owns 40,092 shares of the biotechnology company's stock valued at $2,659,000 after buying an additional 34,521 shares in the last quarter. Principal Financial Group Inc. increased its holdings in Arrowhead Pharmaceuticals by 50.2% in the first quarter. Principal Financial Group Inc. now owns 517,820 shares of the biotechnology company's stock valued at $34,337,000 after buying an additional 173,082 shares in the last quarter. Geneos Wealth Management Inc. increased its holdings in Arrowhead Pharmaceuticals by 121.8% in the first quarter. Geneos Wealth Management Inc. now owns 8,194 shares of the biotechnology company's stock valued at $596,000 after buying an additional 4,500 shares in the last quarter. Fulton Bank N.A. increased its holdings in Arrowhead Pharmaceuticals by 6.5% in the second quarter. Fulton Bank N.A. now owns 4,076 shares of the biotechnology company's stock valued at $337,000 after buying an additional 249 shares in the last quarter. Finally, Sound Income Strategies LLC increased its holdings in Arrowhead Pharmaceuticals by 36.8% in the second quarter. Sound Income Strategies LLC now owns 930 shares of the biotechnology company's stock valued at $77,000 after buying an additional 250 shares in the last quarter. 63.54% of the stock is owned by hedge funds and other institutional investors.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R.

Recommended Story: EV Stocks

Earnings History and Estimates for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Arrowhead Pharmaceuticals right now?

Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.

While Arrowhead Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.